The aim of this study was to characterize the morphological properties of amorphous silica nanoparticles (SiO2 NPs), their cytotoxicity and intracellular location within Human Osteoblasts (HOB). Additionally, SiO2 NPs were explored for their effectivity as carriers of CRTC3-siRNA on Human Preadipocytes (HPAd), and thus downregulate RGS2 gene expression. SiO2 NPs were synthesized using the method of Stöber at 45 °C, 56 °C, and 62 °C. These were characterized via TEM with EDS, Zeta Potential and FT-IR. Cytotoxicity was evaluated by XTT at three concentrations 50, 100 and 500 µg/mL; SiO2 NPs intracellular localization was observed through Confocal Laser Scanning Microscope. Delivering siRNA effectivity was measured by RT-qPCR. Morphology of SiO2 NPs was spherical with a range size from 64 to 119 nm; their surface charge was negative. Confocal images demonstrated that SiO2 NPs were located within cellular cytoplasm. At a SiO2 NPs concentration of 500 µg/mL HOB viability decreased, while at 50 µg/mL and 100 µg/mL cell viability was not affected regardless SiO2 NPs size. SiO2 NPs-CRTC3-siRNA are effective to down-regulate RGS2 gene expression in HPAd without cytotoxic effects. The developed SiO2 NPs-CRTC3-siRNA are a promising tool as a delivery vehicle to control obesity.
ZhangYYuJQiangL, et al. Nanomedicine for obesity treatment. Sci China Life Sci2018; 61: 373–379.
2.
WonYWAdhikaryPPLimKS, et al. Oligopeptide complex for targeted non-viral gene delivery to adipocytes. Nature Mater2014; 13: 1157–1164.
3.
Gómez-HernándezABeneitNDíaz-CastroverdeS, et al. Differential role of adipose tissues in obesity and related metabolic and vascular complications. Int J Endocrinol2016; 2016: 1216783.
4.
SongYAltarejosJGoodarziMO, et al. CRTC3 links catecholamine signaling to energy balance. Nature2010; 468: 933–939.
5.
OuZWangGLiQ, et al. CRTC3 polymorphisms were associated with the plasma level of total cholesterol and the risks of overweight and hypertriglyceridemia in a Chinese Han population. Mol Biol Rep2014; 41: 125–130.
6.
ChakrabartiPKandrorKV.Adipose triglyceride lipase: a new target in the regulation of lipolysis by insulin. Curr Diabetes Rev2011; 7: 270–277.
7.
KimBParkJHSailorMJ.Rekindling RNAi therapy: materials design requirements for in vivo siRNA delivery. Adv Mater2019; 31: e1903637.
8.
BarrosSAGollobJA.Safety profile of RNAi nanomedicines. Adv Drug Deliv Rev2012; 64: 1730–1737.
9.
ShenHHuangXMinJ, et al. Nanoparticle delivery systems for DNA/RNA and their potential applications in nanomedicine. CTMC2019; 19: 2507–2523.
10.
YazdimamaghaniMMoosPJDobrovolskaiaMA, et al. Genotoxicity of amorphous silica nanoparticles: status and prospects. Nanomedicine2019; 16: 106–125.
11.
RindeMKupferschmidtNIqbalMN, et al. Mesoporous silica with precisely controlled pores reduces food efficiency and suppresses weight gain in mice. Nanomedicine2020; 15: 131–144.
12.
KimYHYooHHongAR, et al. NEDD4L limits cAMP signaling through ubiquitination of CREB-regulated transcription coactivator 3. FASEB J2018; 32: 4053–4062.
13.
KlepacKYangJHildebrandS, et al. RGS2: a multifunctional signaling hub that balances brown adipose tissue function and differentiation. Mol Metab2019; 30: 173–183.
14.
StöberWFinkABohnE.Controlled growth of monodisperse silica spheres in the micron size range. J Colloid Interface Sci1968; 26: 62–69.
15.
AssociationWM.World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA2013; 310: 2191–2194.
16.
PfafflMW.A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res2001; 29: e45.
17.
KupferschmidtNCsikaszRIBallellL, et al. Large pore mesoporous silica induced weight loss in obese mice. Nanomedicine2014; 9: 1353–1362.
TomankovaKHorakovaJHarvanovaM, et al. Cytotoxicity, cell uptake and microscopic analysis of titanium dioxide and silver nanoparticles in vitro. Food Chem Toxicol2015; 82: 106–115.
20.
NapierskaDThomassenLCLisonD, et al. The nanosilica hazard: another variable entity. Part Fibre Toxicol2010; 7: 39.
21.
LiSWanQQinZ, et al. Understanding stöber silica's pore characteristics measured by gas adsorption. Langmuir2015; 31: 824–832.
22.
LiMZouPTynerK, et al. Physiologically based pharmacokinetic (PBPK) modeling of pharmaceutical nanoparticles. AAPS J2017; 19: 26–42.
23.
DabbaghianMBabalouAHadiP, et al. A parametric study of the synthesis of silica nanoparticles via sol-gel recipitation method. Int J Nanosci2010; 6: 104–113.
24.
ChithraniBDGhazaniAAChanWC.Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett2006; 6: 662–668.
25.
ManzanoMAinaVAreánCO, et al. Studies on MCM-41 mesoporous silica for drug delivery: effect of particle morphology and amine functionalization. J Chem Eng2008; 137: 30–37.
26.
OsakiFKanamoriTSandoS, et al. A quantum dot conjugated sugar ball and its cellular uptake. On the size effects of endocytosis in the subviral region. J Am Chem Soc2004; 126: 6520–6521.
27.
HeQZhangZGaoF, et al. In vivo biodistribution and urinary excretion of mesoporous silica nanoparticles: effects of particle size and PEGylation. Small2011; 7: 271–280.
28.
HeQZhangZGaoY, et al. Intracellular localization and cytotoxicity of spherical mesoporous silica nano- and microparticles. Small2009; 5: 2722–2729.
29.
MaluginAHerdHGhandehariH.Differential toxicity of amorphous silica nanoparticles toward phagocytic and epithelial cells. J Nanopart Res2011; 13: 5381–5396.
30.
FröhlichE.The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles. Int J Nanomed2012; 7: 5577–5591.
31.
LibermanAMendezNTroglerWC, et al. Synthesis and surface functionalization of silica nanoparticles for nanomedicine. Surf Sci Rep2014; 69: 132–158.
32.
SourisJSChenNTChengSH, et al. Silica nanoparticle platform. In: XChenSWong, eds. Cancer Theranostics. Academic Press, 2014, pp. 363–391.
33.
BehzadiSSerpooshanVTaoW, et al. Cellular uptake of nanoparticles: journey inside the cell. Chem Soc Rev2017; 46: 4218–4244.
34.
Di PasquaAJSharmaKKShiYL, et al. Cytotoxicity of mesoporous silica nanomaterials. J Inorg Biochem2008; 102: 1416–1423.
35.
ZhangQXuHZhengS, et al. Genotoxicity of mesoporous silica nanoparticles in human embryonic kidney 293 cells. Drug Test Anal2015; 7: 787–796.
36.
WatersKMMasielloLMZangarRC, et al. Macrophage responses to silica nanoparticles are highly conserved across particle sizes. J Toxicol Sci2009; 107: 553–569.
37.
ZhaoMYangHJiangX, et al. Lipofectamine RNAiMAX: an efficient siRNA transfection reagent in human embryonic stem cells. Mol Biotechnol2008; 40: 19–26.
38.
BrunoNEKellyKAHawkinsR, et al. Creb coactivators direct anabolic responses and enhance performance of skeletal muscle. EMBO J2014; 33: 1027–1043.
39.
ThanTALouHJiC, et al. Role of cAMP-responsive element-binding protein (CREB)-regulated transcription coactivator 3 (CRTC3) in the initiation of mitochondrial. J Biol Chem2011; 286: 22047–22054.
40.
LuziLRadaelliMG.Influenza and obesity: its odd relationship and the lessons for COVID-19 pandemic. Acta Diabetol2020; 57: 759–764.
41.
ZhangYYuJWenD, et al. The potential of a microneedle patch for reducing obesity. Expert Opin Drug Deliv2018; 15: 431–433.
42.
ZhangYLiuQYuJ, et al. Locally induced adipose tissue browning by microneedle patch for obesity treatment. ACS Nano2017; 11: 9223–9230.
43.
HuBZhongLWengY, et al. Therapeutic siRNA: state of the art. Signal Transduct Target Ther2020; 19: 101.
